We would like to express our sincere gratitude to our sponsors.
Without their invaluable support, this journey wouldn’t have been possible.
The Hellenic Anticancer Institute is a non-profit, philanthropic and scientific foundation established following the decision of the General Assembly of the charitable organization "Christian Social Union" on March 20, 1935. The members of its Board of Directors, prominent figures in Greek society, offer their services without compensation, driven by a strong commitment to the welfare of society and their fellow citizens. Operating independently of government subsidies, the Hellenic Anticancer Institute relies on the support of both prominent and humble Greek citizens who have recognized the valuable work it carries out and have honored it with their generous donations. The Hellenic Anticancer Institute has established and operates a research center on the premises in Athens Greece. This state-of-the-art facility is equipped with modern analytical systems and collaborates with hospitals and universities to conduct high-quality, innovative research programs. It promotes constructive interdisciplinary collaboration between medicine and biology in the contemporary study of cancer. Since January 10, 2019, in accordance with Decision No. 11133 of the Athens Medical Association, the Research Center provides diagnostic services utilizing cutting-edge technology. The foundation is overseen by an eleven-member Board of Directors consisting of university professors, senior judges, and other distinguished scientists. Its work and significant contributions have been acknowledged by prominent Greek citizens, key figures in the country's economic sector, industrialists, professors from Greek and foreign institutions, as well as ordinary individuals who have, through their donations, made substantial contributions to achieving its mission, thereby strengthening its various activities.
Lamda Laboratories, (an Adragos Company), is a European-based innovative contract development company that focuses on providing quality research for generic and generic-plus developments. Lamda Laboratories has a highly experienced team that has worked on over a hundred molecules. Their mission statement is to leverage their extensive expertise and resources for the creation of innovative, niche pharma products with measurable advantages for patients and added value for their partners. Lamda Laboratories’ core values include innovation by promoting industry excellence through creativity and unconventional solutions, flexibility by providing customized service packages to suit their clients’ individual needs, transparency by focusing on ingraining a culture of integrity and commitment by ensuring that their practices, activities and relationships uphold their commitment to value.
The University of Patras was founded in the city of Patras, Greece in 1964 and started to operate in the academic year of 1966-1967. The University is situated in Patras, Agrinion and Messolonghi. The main campus is located 7 km North East of the city of Patras. The University of Patras is the third largest University in Greece in terms of students, faculty members, administrative personnel, number of departments and degrees awarded. It includes 35 Departments covering a wide range of disciplines. It also hosts 161 laboratories and 17 fully equipped clinics. Besides its distinguished path in education, the University of Patras excels in various fields of basic and applied research. The University of Patras has acquired international prominence in research areas such as Health, Environment, Biotechnology, Mechanics, Electronics, Informatics and Basic Science. A number of its academic Departments, laboratories and clinics have been recognized as centres of excellence on the basis of international assessment. The University of Patras has acquired a reputation for producing quality and innovative research and for taking part in a plethora of research projects, scientific organizations and research groups. Together with its educational and research work, the vibrant campus life of the University of Patras attracts many students every year as their first and foremost choice for Higher Education studies.
The “Institute of Cell Therapies” is focused on translational research in cell, gene and regenerative therapies. The institute consists of the following parts/units: 1) The Centre to Advance Public Awareness & Recruitment of Bone Marrow Donor Volunteers (CBMDP) – “Save a Life” which is a fully functional and accredited local registry centre (World Marrow Donor Association code WO-1041) that has already recruited and registered more than 70.000 volunteers resulting in the provision of >150 grafts to patients in Greece and abroad with a sharp increase of provided grafts/year. The CBMDP has received numerous sponsorships and grants from various sources, namely the Stavros Niarchos Foundation (SNF) and Choose Life. 2) The newly founded Cell Therapy Lab fully equipped with specialized infrastructure (GMP clean rooms) (funded by Choose Life ) enabling the introduction, development, and clinical production of “Advanced Therapeutic Medicinal Products” – ATMPs. The ICT is in close collaboration with the Bone Marrow Transplantation Unit of the University General Hospital of Patras (EBMT CIC 281) (www.bmtpatra.gr) for the clinical implementation of advanced cell therapies.
InSyBio is a biotechnology pioneer company in personalized healthcare and nutrition which focuses on developing computational frameworks and tools for the analysis of complex life-science and biological data. The key objective of their analysis lies in discovering predictive integrated biosignatures (biomarkers of various categories) and models with increased prognostic and diagnostic aspects for personalized Healthcare and Nutrition Industries. InSyBio has recently expanded its offering including a complete set of services that allows the personalization of nutrition, nutraceutical, vitamin and probiotic products. These services are built around InSyBio Personalization Test which allows predicting outcomes and satisfaction of each customer using specific products before they even purchase them. InSyBio has developed an online suite of software tools – called InSyBio Suite – which assists biology researchers in extracting valuable biological knowledge from experimental data. The 3 and 12-month licenses of the InSyBio Suite as well as free 1-month licenses of our platform are provided. Some of its methodologies have already been published in international scientific journals and conferences while others are under submission for patent approval by its members.
The Panhellenic Association of Pharmaceutical Industry (PEF) is the institutional body representing the Greek pharmaceutical companies, a large and dynamic sector with significant strategic importance for the National Economy. Greek pharmaceutical companies develop expertise and primarily produce branded generic medicines, adhering strictly to quality assurance (QA) standards and good manufacturing practices (GMP) regulations. It was founded with the aim of contributing to the creation of a conducive operating environment in the Greek pharmaceutical market and its development on the international stage. Within this framework, the Panhellenic Association of Pharmaceutical Industry seeks to advance pharmaceutical science for the benefit of citizens' healthcare and the improvement of their daily quality of life, ensure the complete coverage of the Greek pharmaceutical market with high-quality and cost-effective medicines, promote the healthy growth of the pharmaceutical market and foster the existence of modern and competitive Greek manufacturing facilities to ensure that the Greek pharmaceutical market is not solely reliant on imported medicines.
Boehringer Ingelheim is a global group of companies embracing many cultures and diverse societies. This company is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, it creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term, sustainable perspective. More than 53,000 employees serve over 130 markets in the two business units Human Pharma and Animal Health.
GenScript Biotech Corporation (HK.1548) is the world’s leading technology and service provider of life science R&D and manufacture. Built upon its solid gene synthesis technology, GenScript Biotech is divided into four major platforms including the life science service and product platform, the biologics contract development and manufacturing organization (CDMO) platform, the industrial synthetic products platform, and the integrated global cell therapy platform. Driven by the corporate mission of “make people and nature healthier through biotechnology”, GenScript Biotech strives to become the most trustworthy biotech company in the world.